Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on October 13, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $117.76 ($1,118,720) on October 13, 2026; holds 333,943 after (Indirect).
- Open-market sale: disposed of 639 Common Stock at $542.76 ($346,822) on October 13, 2026; holds 333,304 after (Indirect).
- Open-market sale: disposed of 2,340 Common Stock at $543.48 ($1,271,750) on October 13, 2026; holds 330,964 after (Indirect).
- Open-market sale: disposed of 1,492 Common Stock at $544.56 ($812,483) on October 13, 2026; holds 329,472 after (Indirect).
- Open-market sale: disposed of 1,507 Common Stock at $545.52 ($822,102) on October 13, 2026; holds 327,965 after (Indirect).
- Open-market sale: disposed of 1,452 Common Stock at $546.46 ($793,459) on October 13, 2026; holds 326,513 after (Indirect).
- Open-market sale: disposed of 630 Common Stock at $547.47 ($344,908) on October 13, 2026; holds 325,883 after (Indirect).
- Open-market sale: disposed of 698 Common Stock at $548.49 ($382,844) on October 13, 2026; holds 325,185 after (Indirect).
- Open-market sale: disposed of 502 Common Stock at $549.47 ($275,833) on October 13, 2026; holds 324,683 after (Indirect).
- Open-market sale: disposed of 160 Common Stock at $550.59 ($88,095) on October 13, 2026; holds 324,523 after (Indirect).
- Open-market sale: disposed of 80 Common Stock at $551.49 ($44,119) on October 13, 2026; holds 324,443 after (Indirect).
- Option exercise/conversion: disposed of 9,500 Stock Option on October 13, 2026; holds 242,910 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,182,414 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-13 | Option exercise/conversion | Common Stock | 9,500 | $118 | $1.1M | 333,943 |
| 2026-10-13 | Open-market sale | Common Stock | 639 | $543 | $346.8K | 333,304 |
| 2026-10-13 | Open-market sale | Common Stock | 2,340 | $543 | $1.3M | 330,964 |
| 2026-10-13 | Open-market sale | Common Stock | 1,492 | $545 | $812.5K | 329,472 |
| 2026-10-13 | Open-market sale | Common Stock | 1,507 | $546 | $822.1K | 327,965 |
| 2026-10-13 | Open-market sale | Common Stock | 1,452 | $546 | $793.5K | 326,513 |
| 2026-10-13 | Open-market sale | Common Stock | 630 | $547 | $344.9K | 325,883 |
| 2026-10-13 | Open-market sale | Common Stock | 698 | $548 | $382.8K | 325,185 |
| 2026-10-13 | Open-market sale | Common Stock | 502 | $549 | $275.8K | 324,683 |
| 2026-10-13 | Open-market sale | Common Stock | 160 | $551 | $88.1K | 324,523 |
| 2026-10-13 | Open-market sale | Common Stock | 80 | $551 | $44.1K | 324,443 |
| 2026-10-13 | Option exercise/conversion | Stock Option | 9,500 | — | — | 242,910 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-13 | Option exercise/conversion (9,500 shares) |
| 2026-10-13 | Open-market sale (639 shares) |
| 2026-10-13 | Open-market sale (2,340 shares) |
| 2026-10-13 | Open-market sale (1,492 shares) |
| 2026-10-13 | Open-market sale (1,507 shares) |
| 2026-10-13 | Open-market sale (1,452 shares) |
| 2026-10-13 | Open-market sale (630 shares) |
| 2026-10-13 | Open-market sale (698 shares) |
| 2026-10-13 | Open-market sale (502 shares) |
| 2026-10-13 | Open-market sale (160 shares) |
| 2026-10-13 | Open-market sale (80 shares) |
| 2026-10-13 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.